Experimental drug offered to rare neurological disorder patients
Disease control
AVAILABLE
This program provides access to the investigational drug troriluzole for people with spinocerebellar ataxia (SCA), a rare genetic disorder that affects movement and coordination. The program is designed for patients who have a confirmed SCA diagnosis and may include both new pati…
Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC